Related Experiment Video
Updated: Aug 16, 2025
Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
Published on: February 2, 2024
Cutibacterium acnes Prosthetic Joint Infections: Is Rifampicin-Combination Therapy Beneficial?
Grégoire Saltiel1,2, Vanina Meyssonnier1,2, Younes Kerroumi1
1Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d'Avron, 75020 Paris, France.
Abstract:
No consensus has been reached on the optimal antibiotic regimen to treat Cutibacterium acnes PJIs (Ca-PJIs). In vitro studies showed excellent rifampicin efficacy against biofilm-associated C. acnes infections, but clinical studies did not confirm the superiority of rifampicin-combined therapy over monotherapy. This prospective cohort study was undertaken to analyze the outcomes of 70 patients who underwent exchange arthroplasty for chronic monomicrobial Ca-PJI and were treated with rifampicin or without between 2004 and 2019. The 37 patients treated from January 2004 to August 2014 were prescribed rifampicin-combination therapy and the 33 treated from September 2014 to December 2019 received monotherapy without rifampicin. The primary endpoint was the 2-year Kaplan-Meier-estimated reinfection-free probability, including relapses and new-pathogen PJIs. The 2-year reinfection-free rate was high and not different for patients who had received rifampicin or not (89.2% vs. 93.8%, respectively; p = 0.524). None of the patients relapsed and six developed new-pathogen PJIs. Our results do not support a benefit of rifampicin-combination therapy for patients who underwent exchange arthroplasty for chronic Ca-PJIs.
Insights
Rifampicin combination therapy did not improve outcomes for patients with chronic Cutibacterium acnes prosthetic joint infections (Ca-PJIs) undergoing exchange arthroplasty. The 2-year reinfection-free rates were similar with or without rifampicin.
Area of Science:
- Orthopedics
- Infectious Diseases
- Pharmacology
Background:
- Optimal antibiotic treatment for Cutibacterium acnes prosthetic joint infections (Ca-PJIs) remains unclear.
- In vitro studies suggest rifampicin is effective against biofilm-associated C. acnes, but clinical evidence is lacking.
- Previous clinical studies have not confirmed rifampicin-combination therapy's superiority over monotherapy.
Purpose of the Study:
- To analyze the outcomes of patients with chronic monomicrobial Ca-PJI treated with or without rifampicin.
- To compare the 2-year reinfection-free probability in patients undergoing exchange arthroplasty for Ca-PJI.
Main Methods:
- Prospective cohort study of 70 patients with chronic monomicrobial Ca-PJI undergoing exchange arthroplasty.
- Patients were divided into two groups: rifampicin-combination therapy (n=37) and monotherapy without rifampicin (n=33).
- Primary endpoint was the 2-year Kaplan-Meier-estimated reinfection-free probability.
Main Results:
- The 2-year reinfection-free rate was high in both groups (89.2% with rifampicin vs. 93.8% without rifampicin; p=0.524).
- No patients experienced relapse of Ca-PJI.
- Six patients developed new-pathogen PJIs.
Conclusions:
- Rifampicin-combination therapy does not appear to offer a benefit for patients undergoing exchange arthroplasty for chronic Ca-PJIs.
- The study suggests that standard monotherapy may be sufficient for treating these infections.
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Antimicrobial Effectiveness